Back to School: How biopharma can reboot drug development. Access exclusive analysis here

KATP blocker 1908: AVE said it discontinued development of KATP blocker 1908, which was in Phase IIa testing. The company also discontinued development of metab

Aventis S.A. (AVE), Strasbourg, France
Product: KATP

Read the full 75 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE